RSS   Newsletter   Contact   Advertise with us
Post Online Media

Edge appoints Harry Sacks as VP, clinical development

EdgeEdge Therapeutics, Inc., a clinical-stage biotechnology company, announced that Harry J. Sacks has joined Edge as its vice president, clinical development, effective June 20, 2016.
Dr. Sacks has approximately 20 years of clinical development experience in the pharmaceutical and biotechnology industries, including directing clinical program oversight from early stages, through development and beyond marketing approval.

Prior to joining Edge, Dr. Sacks held roles of increasing responsibility at Novartis, where he most recently served as Vice President, Medical and Scientific Affairs, and Medical Respiratory Head in U.S. Clinical Development and Medical Affairs.

In this role, Dr. Sacks led medical strategy for the respiratory franchise in the U.S., including overseeing clinical development programs and execution of the medical product plans for Xolair, Utibron Neohaler and Tobi Podhaler.

Prior to Novartis, Dr. Sacks served in leadership roles at Forest Research Institute, Meda Pharmaceuticals (formerly MedPointe Pharmaceuticals) and Schering-Plough Research Institute.

Dr. Sacks holds an M.D. with special distinction in research from the Albert Einstein College of Medicine and a B.A. in biology and Judaic studies from Yeshiva University.

He trained in pediatrics and anesthesiology, is board certified by the American Board of Pediatrics and is a Fellow of the American Academy of Pediatrics. He is a member of the American Thoracic Society and the American Academy of Allergy, Asthma and Immunology.




We use cookies to ensure that we give you the best experience on our website. Please allow cookies for fully-functioning website.

Allow Cookies Privacy Policy